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Abstract
STAT5A (signal transducer and activator of transcription 5A) is a transcription factor
that plays a role in adipocyte development and function. In this study, we report DBC1
(deleted in breast cancer 1 – also known as CCAR2) as a novel STAT5A-interacting protein.
DBC1 has been primarily studied in tumor cells, but there is evidence that loss of this
protein may promote metabolic health in mice. Currently, the functions of DBC1 in
mature adipocytes are largely unknown. Using immunoprecipitation and immunoblotting
techniques, we confirmed that there is an association between endogenous STAT5A
and DBC1 proteins under physiological conditions in the adipocyte nucleus that is not
dependent upon STAT5A tyrosine phosphorylation. We used siRNA to knockdown
DBC1 in 3T3-L1 adipocytes to determine the impact on STAT5A activity, adipocyte gene
expression and TNFα (tumor necrosis factor α)-regulated lipolysis. The loss of DBC1 did
not affect the expression of several STAT5A target genes including Socs3, Cish, Bcl6,
Socs2 and Igf1. However, we did observe decreased levels of TNFα-induced glycerol and
free fatty acids released from adipocytes with reduced DBC1 expression. In addition,
DBC1-knockdown adipocytes had increased Glut4 expression. In summary, DBC1 can
associate with STAT5A in adipocyte nucleus, but it does not appear to impact regulation
of STAT5A target genes. Loss of adipocyte DBC1 modestly increases Glut4 gene expression
and reduces TNFα-induced lipolysis. These observations are consistent with in vivo
observations that show loss of DBC1 promotes metabolic health in mice.
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Introduction
Signal transducer and activator of transcription 5A
(STAT5A) is a transcription factor that utilizes the janus
kinase/signal transducer and activator of transcription
(JAK/STAT) pathway to mediate the biological actions
of a variety of hormones and cytokines. In vivo and in
vitro approaches have demonstrated that STAT5A has
a prominent role in adipogenesis (Teglund et al. 1998,
Floyd & Stephens 2003, Stewart et al. 2011, Wakao
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et al. 2011, Tse et al. 2013). Growth hormone (GH) is a
primary activator of STAT5A in adipocytes. Upon GH
activation, STAT5A can activate or repress several genes
including suppressor of cytokine signaling 3 (Socs3),
cytokine-inducible SH2-containing protein (Cish), B-cell
lymphoma 6 (Bcl6), fatty acid synthase (Fasn), adiponectin
and pyruvate dehydrogenase kinase 4 (Pdk4) in adipocytes
(Hogan & Stephens 2005, Story & Stephens 2006, White
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et al. 2007, 2016, Lin et al. 2014). Despite the identification
of these direct STAT5 target genes, very little is known
about the molecular mechanisms that contribute to
the ability of STAT5A to regulate gene expression in
adipocytes. To further investigate the functions of
STAT5A in adipocytes, we sought to identify novel
proteins that interact with STAT5A by performing a nonbiased co-immunoprecipitation and mass spectrometry
approach (Richard et al. 2017). This approach identified
DBC1 (deleted in breast cancer 1) as a potential STAT5Ainteracting protein.
DBC1, also referred to as CCAR2 (cell cycle and
apoptosis regulator 2), is a pleiotropic protein that is
primarily localized in the nucleus. DBC1 has been shown
to physically interact and negatively regulate several
epigenetic modifiers including sirtuin 1 (SIRT1), histone
deacetylase 3 (HDAC3) and suppressor of variegation 3–9
homolog 1 (SUV39H1) (Zhao et al. 2008, Li et al. 2009,
Chini et al. 2010). SIRT1 is a NAD-dependent deacetylase
involved in a variety of cellular processes including
regulation of obesity-associated metabolic diseases, cancer,
aging and cellular senescence (Rahman & Islam 2011). A
loss of DBC1 expression is associated with increased SIRT1
activity in A459 human alveolar basal epithelial cells (Zhao
et al. 2008). DBC1 also interacts and negatively regulates
estrogen receptor β (ERβ) and breast cancer 1 susceptibility
protein 1 (BRCA1) (Hiraike et al. 2010, Koyama et al. 2010).
In addition, DBC1 can be present in a complex with and
positively regulate estrogen receptor α (ERα), androgen
receptor (AR) and nuclear receptor subfamily 1, group D,
member 2 (Rev-erbα) (Fu et al. 2009, Yu et al. 2011, Chini
et al. 2013). DBC1 has also been shown to physically
interact with and positively regulate IKK-α and IKK-β; two
kinases that are part of the inhibitor of kappa B Kinase
(IKK) complex that affects nuclear factor kappa B (NF-κB)
signaling and transcriptional activity (Kong et al. 2015).
To date, most DBC1 studies have been performed
in tumor cells and little is known about the function of
DBC1 in adipocytes. However, studies have shown that
knockdown of DBC1 in 3T3-L1 preadipocytes promotes
adipocyte development in vitro (Moreno-Navarrete et al.
2015a). Also, DBC1-knockout mice have increased fat
accumulation in adipose tissue, but remain metabolically
healthy (Escande et al. 2015). DBC1-knockout mice
maintained insulin sensitivity, had lower circulating free
fatty acids and were protected against atherosclerosis and
liver steatosis following diet-induced obesity (Escande
et al. 2015). Other studies have shown that loss of DBC1
in 3T3-L1 adipocytes results in decreased expression
of inflammatory markers such as interleukin 6 (IL-6),
https://jme.bioscientifica.com
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monocyte chemoattractant protein 1 (MCP1) and tumor
necrosis factor-alpha (TNFα), indicating that DBC1 may
influence adipocyte inflammation (Moreno-Navarrete
et al. 2015b). DBC1 has also been implicated in senescence
of preadipocytes as loss of DBC1 protects again cellular
senescence and senescence-driven inflammation in
obesity (Escande et al. 2014).
Our studies are the first to show that DBC1 is present
in a complex with STAT5A under physiological conditions
in the nucleus of adipocytes. However, knockdown
approaches revealed that DBC1 does not have a profound
effect on the ability of GH to regulate STAT5 target genes.
In studies to observe an impact of DBC1 loss in adipocytes,
we found that DBC1 can impact TNFα-mediated lipolysis
in mature 3T3-L1 adipocytes. Although DBC1 did not have
a profound effect on TNFα-mediated changes in Mcp-1
or adiponectin expression, the loss of DBC1 resulted in
increased Glut4 expression.

Materials and methods
Cell culture
Murine 3T3-L1 preadipocytes (obtained from Dr Howard
Green at Harvard University) were grown in Dulbecco’s
Modified Eagle’s Media (DMEM) (Sigma-Aldrich) with
10% bovine calf serum. Two days after confluence,
the preadipocytes were induced to differentiate using
a standard protocol and 3-isobutyl-methylxanthine,
dexamethasone, insulin (MDI) induction cocktail plus
10% fetal bovine serum (FBS) in DMEM (Richard et al.
2017). HyClone calf and FBS were purchased from Thermo
Scientific or GE Healthcare Life Sciences (Marlborough,
MA). The medium was changed every 48–72 h during
growth and differentiation. Cells were serum deprived
by changing the medium to DMEM containing 1% calf
serum for 16–24 h before treatment with murine GH
(mGH) or murine TNFα. Recombinant murine GH was
obtained from Dr. A.F. Parlow at the National Hormone
and Peptide Program (NHPP; Torrance, CA). Recombinant
murine TNFα was purchased from Thermo Fisher (Cat #:
PMC3013).
siRNA-mediated knockdown
3T3-L1 adipocytes (5–7 days post-MDI) were trypsinized
and re-plated in 6-well, 12-well or 24-well plates at a
density of 5.8 × 105 cells/cm2 in antibiotic-free medium
(10% FBS/DMEM). Using the protocol from Dharmacon,
adipocytes were transfected with 50 nM siRNA
(Dharmacon, Lafayette, CO, USA; Non-targeting siRNA Cat
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#: D-001810-10-50, siRNA targeting DBC1 Cat #: L-04783700-0005) and the DharmaFECT Duo reagent (Dharmacon,
Cat #: T-2010-03) in OptiMEM reduced serum medium
(Thermo Fisher; Cat #: 31985088). Non-targeting siRNA
was used as negative control. After 24 h, siRNA-containing
media was removed, replaced with antibiotic-free 10%
FBS/DMEM and cells were transfected again with 50 nM
siRNA. After 24 h, the media was removed and replaced
with antibiotic-free 10% FBS/DMEM. Cell monolayers
were collected 72 h following the initial transfection and
harvested for protein in immunoprecipitation (IP) buffer,
and for RNA in buffer provided in the RNeasy mini kit
(Qiagen) to assess knockdown efficiency. Knockdown
of Cyclophilin B was used as a positive control to assess
siRNA transfection efficiency in 3T3-L1 adipocytes
because it is a well-characterized housekeeping gene that
is not affected by experimental treatments in adipocytes
and has been validated in our lab. (Dharmacon; Cat #:
D-001820-02-05).
RNA analysis
Adipocyte monolayers were harvested in lysis buffer
from the RNeasy mini kit and total RNA was isolated
from harvested cells using the RNeasy mini kit (Qiagen).
Ten microliters of purified RNA were used for reverse
transcription (RT) PCR to generate cDNA according to
the Applied Biosystems protocol (Applied Biosystems;
Cat #: 4368813). cDNA was quantitated using the realtime quantitative PCR (qPCR) method in a total volume
of 10 µL (2 µL DNA and 8 µL reaction master mix) using
an Applied Biosystems 7900HT Fast Real-Time PCR
System and the qPCR amplification program specified in
the kit (Clontech, Mountain View, CA; Cat #: RR420A).
Cyclophilin B (Ppib), Ubiquitin B (Ubb) and Nono were
used as endogenous controls. The following mouse genes
were examined by RT-qPCR: Ppib, Ubb, Nono, Dbc1 (Ccar2),
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Socs3, Cish, Bcl6, Igf1, Mcp1, Glut4 and adiponectin
(Adipoq) using primers purchased from Integrated DNA
Technologies (IDT, Coralville, IA, USA). Primer sequences
for each gene are shown in Table 1.
Whole-cell extract preparation
Adipocyte monolayers were rinsed once with PBS and
then harvested in non-denaturing IP buffer as previously
described (Richard et al. 2017). The cell extract was
subjected to a freeze/thaw cycle at −80°C and then passed
through a 20-gauge needle three times. The whole-cell
extract was further purified by centrifugation at 13,000 g
for 10 min at 4°C.
Subcellular fractionation
Mature 3T3-L1 adipocytes were treated with vehicle or
murine GH prior to subcellular fractionation. Adipocyte
monolayers from twenty 10 cm culture plates were scraped
into nuclear homogenization buffer (NHB) (20 mM Tris pH
7.4, 10 mM NaCl, and 3 mL MgCl2) as previously described
(Richard et al. 2017). After adding 0.15% IGEPAL CA-630
(from 10% stock) to the cell suspension, it was homogenized
on ice using 16 strokes in a Dounce homogenizer. The extract
was centrifuged at 517 g in a Beckman GS-6KR centrifuge
with a swinging bucket rotor. Subsequently, the supernatant
containing cytosol and mitochondria was centrifuged
as previously described (Richard et al. 2017). The nuclear
pellet from the first centrifugation was washed once with
half of the initial volume of NHB buffer and re-centrifuged
at 4°C for 5 min at 57 g in the Beckman GS-6KR centrifuge.
The supernatant was discarded, while the nuclear pellet
was resuspended in IP buffer and incubated on ice for 1 h.
To break open the nuclei, the nuclear extract was passed
through a 20G needle four times and further purified by
centrifuging at 13,000 g for 10 min at 4°C.

Table 1 Primer sequences for each gene examined by real-time qPCR.
Gene

Primer 1 sequence

Primer 2 sequence

Ppib
Ubb
Nono
Dbc1 (Ccar2)
Socs3
Cish
Bcl6
Igf1
Mcp1
Glut4
Adiponectin

5′-CCGTAGTGCTTCAGCTTGA-3′
5′-GCTTACCATGCAACAAAACCT-3′
5′-TCTTCAGGTCAATAGTCAAGCC-3′
5′-TGCGTTTCTTCGAGTCATAGT-3′
5′-TAGACTTCACGGCTGCAAC-3′
5′-CCGCCCAATTTGCTCCA-3′
5′-AGTCACATTCGTTGCAGAAGA-3′
5′-AGTACATCTCCAGTCTCCTCAG-3′
5′-GCAGAGAGCCAGACGGGAGGA-3′
5′-TCTTATTGCAGCGCCTGAG-3′
5′-GCAGGATTAAGAGGAACAGGAG-3′

5′-AGCAAGTTCCATCGTGTCATC-3′
5′-CCAGTGGGCAGTGATGG-3′
5′-CATCATCAGCATCACCACCA-3′
5′-CTTCCAGACATCCCACACAC-3′
5′-CGGGGAGCTAGTCCCGAA-3′
5′-GCTCCTTTCTCCTTCCATCC-3′
5′-CAGAGATGTGCCTCCATACTG-3′
5′-ATGCTCTTCAGTTCGTGTGT-3′
5′-TGGGGCGTTAACTGCATCTGG-3′
5′-GAGAATACAGCTAGGACCAGTG-3′
5′-TGTCTGTACGATTGTCAGTGG-3′
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Measurement of protein concentration
Protein content of cell extracts was quantified using the
Bicinchoninic acid (BCA) assay kit (Sigma-Aldrich; Cat #:
BCA1).
Gel electrophoresis and immunoblotting
Samples were separated on 7.5, 10 or 15% SDS-PAGE
(acrylamide; National Diagnostics, Atlanta, GA, USA; Cat
#: EC-890) and transferred to nitrocellulose membranes
(BioRad; Cat #: 162-0115) in 25 mM Tris, 192 mM glycine
and 20% methanol. After the transfer, the membrane was
blocked in 4% milk for 1 h at room temperature and then
immunoblotted. Results were visualized with horseradish
peroxidase-conjugated secondary antibodies (Jackson
ImmunoResearch) and enhanced chemiluminescence
(Pierce/Thermo Scientific).
Immunoprecipitation (IP)
Cell extracts (300–400 µg total protein) were incubated
with 4–5 µg of immunoprecipitating antibody, diluted
in IP buffer, overnight on a mini-tube rotator at 4°C.
Protein A-conjugated agarose beads (IPA300 Protein A
Resin; Repligen, Waltham, MA, USA; Cat #: 10-2003-02)
were added to the antibody-epitope mixture, and the
conjugation reaction proceeded for an additional 3–4 h
at 4°C with rotation. Following conjugation to the bead
resin, the beads were pelleted by centrifugation at 16,750
g for 3 min at 4°C. The supernatant was removed by
aspiration and the beads were washed three times with
ice cold 1X IP buffer. Between each wash, the beads were
pelleted by centrifugation at 13,000 g for 3 min at 4°C
and the supernatant was removed by aspiration. After
the final wash, the IP antibody and immunoprecipitated
proteins were eluted from the bead resin into 2× SDS
loading buffer by boiling the samples for 10 min at
100°C. Samples were flicked every 2 min during heat
step to ensure efficient elution. The samples were briefly
centrifuged and the supernatants were analyzed by
SDS-PAGE and immunoblotting. A mock sample
containing only IP antibody and IP buffer (no cell extract)
was used as a negative control for each IP experiment.
SIRT1 activity measurement
The deacetylase activity of SIRT1 was measured using a
fluorometric assay kit (Enzo Life Sciences, Farmingdale,
NY, USA; Cat #: BML-AK500–0001). Cell extracts (75 µg
total protein) were incubated with 5 µg of anti-SIRT1
https://jme.bioscientifica.com
https://doi.org/10.1530/JME-18-0154

© 2018 Society for Endocrinology
Published by Bioscientifica Ltd.
Printed in Great Britain

Effects of DBC1 knockdown in
adipocytes in vitro

61 :4

198

antibody using the immunoprecipitation method
described earlier. After the final wash, the samples were
resuspended in 100 µL of assay buffer provided by the
assay kit. The manufacturer’s instructions were followed
and optimized for our samples. Briefly, the deacetylase
reaction was initiated by adding 50 µM of Fluor de lys
substrate and 1 mM NAD+ (SIRT1 substrate) to samples.
After incubating the samples for 20 min at room
temperature, the reactions were stopped by addition
of 1X Fluor de lys developer that contained either 1 µM
trichostatin A (TricA; HDAC inhibitor) or 2 mM of
nicotinamide (NAM; SIRT1 inhibitor). Samples were
read in a fluorometer (SpectraMax M5) at an excitation
wavelength of 360 nm and emission wavelength of
460 nm.
Measurement of glycerol and free fatty acid release
3T3-L1 adipocytes were transfected with either nontargeting or DBC1 siRNA as described above. Fifty-four
hours later, media was changed to 1% calf/DMEM and
cells were treated with equivalent volume of vehicle
(0.1% BSA/PBS) or 0.75 nM TNFα overnight. After
16 h, 1% calf/DMEM was removed and replaced with
incubation media that consisted of 2% fatty acid free
bovine serum albumin (BSA; Sigma-Aldrich; Cat #:
A6003) and 0.1% glucose in glucose-free phenol red-free
DMEM, and the cells were treated again with vehicle
(0.1% BSA/PBS) or 0.75 nM TNFα. After 2 h, 500 μL of
conditioned media was collected and stored at −20°C.
Glycerol release was measured using 50 μL of each
sample according to the kit protocol (Millipore; Cat #:
OB100). Free fatty acid release was measured using 50 μL
of each sample according to the kit protocol (BioVision,
Milpitas, CA, USA; Cat #: K612).
Antibodies
Anti-STAT5A (L-20; sc1081; rabbit polyclonal) and
anti-ERK1/2 (C-16; sc-93; rabbit polyclonal) antibodies
were purchased from Santa Cruz Biotechnology. We
used both mouse monoclonal (clone 8-5-2; 05-495)
and rabbit polyclonal (07-586) anti-phospho-STAT5
A/B (Tyr 694/699) antibodies from Millipore to detect
tyrosine phosphorylated STAT5 (STAT5pY). Antiadiponectin (PA1-054; rabbit polyclonal) antibody was
purchased from Thermo Scientific. Anti-DBC1 (5693;
rabbit polyclonal) and anti-SIRT1 (1F3; 8469; mouse
monoclonal) antibodies were purchased from Cell
Signaling Technology.
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Statistical analysis
All data were analyzed by two-tailed unpaired Student’s
t-test (using GraphPad Prism 7). Results from studies of
cultured adipocytes are shown as mean ± standard error
of the mean (s.e.m.). Results were considered statistically
significant when P < 0.05.

Results
We previously utilized a semi-nonbiased screening
approach to identify novel STAT5 interaction partners
using co-immunoprecipitation and mass spectrometry.
Pyruvate dehydrogenase complex-E2 (PDC-E2) was
the first interacting protein that we reported from this
screen (Richard et al. 2017). In our present study, we
report that DBC1 was also identified as a potential novel
STAT5A-interacting protein in 3T3-L1 adipocytes. To
validate our mass spectrometry results, we performed
co-immunoprecipitation with a STAT5A antibody followed
by Western blotting using an anti-DBC1 antibody, and
we examined both cytosolic and nuclear extracts from
mature 3T3-L1 adipocytes in the absence or presence of
an acute GH treatment, a condition that activates STAT5A
(Fig. 1A). These studies revealed that DBC1 interacts with
STAT5A in the nucleus and that the nuclear localization of
DBC1, unlike STAT5A, was not dependent on GH-induced
STAT5 tyrosine phosphorylation (Fig. 1A). To further
validate that these two proteins were present in the
same protein complex in adipocytes, we demonstrated
that STAT5A could also be pulled down by a reverse
co-immunoprecipitation using a DBC1 antibody (Fig. 1B).
Together, these experiments corroborate that DBC1 is
present in a complex with STAT5A under physiological
conditions in the nucleus of adipocytes and that this
interaction is not dependent upon GH stimulation or
STAT5 tyrosine phosphorylation.
To assess the function of the DBC1/STAT5A interaction,
we performed siRNA experiments to knockdown DBC1 in
mature adipocytes. The goal was to determine if DBC1
expression had any effect on STAT5 phosphoactivation or
transcriptional activity. In these studies, we examined the
ability of GH to induce STAT5A activation by measuring
STAT5A tyrosine phosphorylation. Western blot analysis
showed that loss of DBC1 levels did not have an effect on
levels of STAT5A or STAT5pY (Fig. 2).
To confirm that the loss of DBC1 protein affected
its activity in adipocytes, we performed additional
experiments to measure SIRT1 activity. It is well established
that SIRT1 activity is negatively regulated by DBC1 (Kim
https://jme.bioscientifica.com
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Figure 1
DBC1 is present in the nucleus of adipocytes and can be
co-immunoprecipitated with STAT5A. (A) Fully differentiated 3T3-L1
adipocytes were treated with 5 nM murine growth hormone (GH) or an
equivalent volume of vehicle (10 mM NaHCO3) for 20 min. Monolayers
were collected and subjected to subcellular fractionation. As shown in
the left-hand portion of the figure, cytosolic and nuclear protein extracts
(300 µg total protein/sample) were immunoprecipitated (IP) with an
anti-STAT5A antibody. The mock sample contained anti-STAT5A antibody
without cell extract. The right-hand portion of the figure are direct
Western blot (WB) controls containing 75 µg total protein that were
directly subjected to Western blotting without IP. STAT5pY represents
phosphorylated STAT5 at tyrosine 694/699. This is a representative figure
of an experiment independently performed three times. (B) The
monolayers of fully differentiated 3T3-L1 adipocytes were harvested and
whole-cell protein extracts were prepared. The left-hand portion of the
figure shows IP of whole-cell extract containing 400 µg of total protein,
anti-DBC1 antibody and IP buffer. Mock sample contained anti-DBC1
antibody without cell extract. The right-hand portion of the figure
contains WB controls. This is a representative figure of an experiment
independently performed three times on different groups of adipocytes.

et al. 2008, Zhao et al. 2008). As expected, our experiments
showed an increase in SIRT1 activity when DBC1 protein
levels were reduced (***P < 0.001), suggesting that the
knockdown of DBC1 also affected its activity in adipocytes
as judged by SIRT1 activity (Fig. 3A). Induction of SIRT1
deacetylase activity in HeLa extract with the addition of
NAD+ or trichostatin A (TricA) was used as a control to
confirm validity of the deacetylase assay (Fig. 3B).
Tyrosine phosphorylated STAT5A can activate or
repress the expression of many genes. To determine if
DBC1 expression had any effect on the transcriptional
activity of STAT5, we examined the expression of several
STAT5 target genes following GH treatment of mature
adipocytes for 1–4 h under control or DBC1-knockdown
conditions. The expression of STAT5A target genes (Socs3,
Cish and Bcl6) was assessed by qPCR. It is known that
Socs3 and Cish gene expression are highly induced 1 h
following STAT5 activation (Matsumoto et al. 1997,
Karlsson et al. 1999, Barclay et al. 2007), whereas Bcl6 gene
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Figure 2
Knockdown of DBC1 does not affect STAT5A protein expression or STAT5
tyrosine phosphorylation in 3T3-L1 adipocytes. Fully differentiated 3T3-L1
adipocytes were transfected once per day for 2 days with non-targeting
siRNA or DBC1 siRNA. After 48 h, adipocytes were serum deprived for 4 h
and treated with 5 nM murine growth hormone (GH) or equivalent
volume of vehicle (10 mM NaHCO3) for 20 min. Monolayers were collected
and 75 μg of total protein was separated using SDS-PAGE. Protein
expression was visualized using Western blotting with the antibodies
indicated to the left of panel. ERK was used as a loading control. Three
biological replicates were used for each treatment group in each
individual experiment. This is a representative figure of an experiment
independently performed three times on different groups of adipocytes.

expression is reduced following 4 h of GH treatment (Lin
et al. 2014). The data showed the expected regulation of
Socs3, Cish and Bcl6 gene expression following 1 h of GH
treatment. However, there were no differences in mRNA
levels of these genes in adipocytes with reduced DBC1
expression (Fig. 4). Similar results were observed for other
STAT5A target genes such as adiponectin, Fasn and Pdk4
(data not shown).
Although DBC1 did not have a profound impact
on STAT5A transcriptional activity, there is evidence
in the literature that DBC1 may affect adipose tissue
inflammation (Moreno-Navarrete et al. 2015b). We
explored this on the cellular level by investigating the
ability of DBC1 to modulate TNFα action in adipocytes.
TNFα is known to increase basal lipolysis, promote the
expression and secretion of pro-inflammatory cytokines,
such as IL-6, and reduce the secretion of anti-inflammatory
hormones, such as adiponectin (Berghe et al. 2000, He
et al. 2016). To investigate the effects of DBC1 on TNFα
action, we used siRNA to knockdown DBC1 in mature
3T3-L1 adipocytes. Gene expression analysis showed that
a loss of DBC1, independent of TNFα treatment, increased
Glut4 gene expression (***P < 0.01 for Vehicle treatment
and **P < 0.01 for TNFα treatment) but did not have a
profound effect on TNFα-mediated changes in expression
of Mcp1 or adiponectin (Fig. 5A). Western blot analysis was
used to assess the level of DBC1 protein knockdown and
the effectiveness of TNFα treatment, as judged by reduced
adiponectin protein levels (Fig. 5B), which was consistent
https://jme.bioscientifica.com
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Figure 3
Knockdown of DBC1 increases the deacetylase activity of SIRT1 in 3T3-L1
adipocytes. (A) SIRT1 deacetylase activity was measured in samples
prepared by immunoprecipitating SIRT1 from 3T3-L1 adipocytes
transfected with non-targeting (NT) or DBC1 siRNA. Each IP reaction
contained 75 μg of total protein, anti-SIRT1 antibody and IP buffer.
(B) HeLa extract was used as a control to assess SIRT1 deacetylase activity.
The graph shows the requirement of NAD+ for SIRT deacetylase activity
and Trichostatin A (TricA) inhibiting the Fluor de Lys substrate
deacetylation in HeLa nuclear extract. Statistical significance was
determined using a Student’s t-test and assigned as ***P < 0.001.

with the changes observed in adiponectin gene expression
(Fig. 5A). We also assessed whether DBC1 expression had
an impact on TNFα-mediated lipolysis. Both free fatty
acid and glycerol release were measured from mature
adipocytes following TNFα treatment in control and
DBC1-knockdown adipocytes. We observed a modest, but
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Figure 4
Knockdown of DBC1 in mature adipocytes does
not affect the ability of GH to alter the expression
of STAT5A target genes. Fully differentiated
3T3-L1 adipocytes were transfected once per day
for two days with non-targeting (NT) siRNA or
DBC1 siRNA. After 48 h, adipocytes were serum
deprived for 4 h and treated with 5 nM murine
growth hormone (GH) or equivalent volume of
vehicle (V; 10 mM NaHCO3) for 1, 2, or 4 h. Total
RNA was isolated and subjected to quantitative
RT-PCR analysis. Each graph represents a different
gene. The examined genes were normalized to
Nono. This is a representative figure of an
experiment independently performed three times
on different groups of adipocytes.

statistically significant, decrease in TNFα-induced glycerol
(***P < 0.005) and free fatty acid (*P < 0.05) release with
reduced DBC1 expression (Fig. 6).

Discussion
STAT5A is a transcription factor that can mediate the
effects of GH (Zvonic et al. 2003) and promote adipocyte
development (Floyd & Stephens 2003, Stewart et al. 2011).
In adipocytes, STAT5A regulates genes that contribute
to insulin sensitivity and the endocrine properties of
adipocytes (Hogan & Stephens 2005, White et al. 2007,
2016). To further understand the mechanisms involved
in the contribution of STAT5A to fat cell function, we
sought to identify novel STAT5A-interacting proteins
in adipocytes using a co-immunoprecipitation/mass
spectrometry approach. We recently published data
describing this approach and the identification of
components of the pyruvate dehydrogenase complex as
STAT5A-binding proteins (Richard et al. 2017). Another
STAT5A-binding protein that we identified with this
approach was the nuclear protein, DBC1. DBC1 has been
shown to mediate cellular responses to stress and regulate
the activity of a variety of enzymes and transcription
factors in different cell types (Joshi et al. 2013). Our novel
observations demonstrate that DBC1 can be present in
the same protein complex as STAT5A in the nucleus of
3T3-L1 adipocytes (Fig. 1). This interaction was observed
with endogenous proteins and could be detected by
https://jme.bioscientifica.com
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immunoprecipitating either STAT5A or DBC1. In addition
to this observation, our results reveal that this interaction
is not dependent on STAT5A tyrosine phosphorylation
(Fig. 1A).
To assess the potential function of the STAT5A/DBC1
association, we examined STAT5A expression levels as
well as STAT5A tyrosine phosphorylation in adipocytes
that had substantially decreased levels of DBC1. These
studies revealed that loss of DBC1 did not alter STAT5A
total protein levels or its ability to be activated, as judged
by tyrosine phosphorylation (Fig. 2). We also examined
the ability of STAT5A to regulate gene expression in
adipocytes with reduced DBC1 expression. To our surprise,
there were no profound changes in the expression of
several STAT5A target genes in DBC1-deficient adipocytes,
which strongly indicates that DBC1 levels do not affect
the transcriptional activity of STAT5A (Fig. 4). Although
there were some modest differences in Socs3 and Cish
gene expression following 4-h GH treatment in DBC1
knockdown adipocytes, these results were not statistically
significant. The effectiveness of siRNA-mediated DBC1
knockdown was assessed by examining gene and protein
expression levels of DBC1 (Figs 2, 4 and 5) as well as SIRT1
deacetylase activity (Fig. 3) since DBC1 is a well-known
negative regulator of SIRT1 (Kim et al. 2008, Zhao et al.
2008, Liu et al. 2016). As expected, we observed an increase
in SIRT1 activity, indicating that the activity of DBC1 was
likely altered in the DBC1-knockdown adipocytes (Fig. 3).
Presumably, we only observed a modest increase in SIRT1
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Figure 5
Knockdown of DBC1 in mature adipocytes results
in increased Glut4 gene expression but does not
alter TNFα-mediated changes in gene expression.
Fully differentiated 3T3-L1 adipocytes were
transfected once per day for two days with
non-targeting (NT) siRNA or DBC1 siRNA. After
54 h, media was replaced with 1% calf and cells
were treated with 0.75 nM TNFα overnight or
equivalent volume of vehicle (0.1% BSA/PBS).
After 16 h, cells were re-treated again with vehicle
or TNFα for 2 h. Finally, monolayers were
harvested for RNA and protein. (A) Total RNA was
isolated and subjected to quantitative RT-PCR
analysis. The examined genes (each represented
by separate graph) were normalized to Nono.
Statistical significance was determined using a
Student’s t-test and assigned as **P < 0.01,
***P < 0.001, and ****P < 0.0001. (B) 75 μg of total
protein was separated using SDS-PAGE. Protein
expression was visualized using Western blotting
and the antibodies indicated on the left of panel.
Three biological replicates were used for each
treatment group in each individual experiment.
This is a representative figure of an experiment
independently performed three times on
different groups of adipocytes.

activity because DBC1 is only one of many regulators of
SIRT1 activity in mature adipocytes. Other studies have
shown that a variety of other factors including the cAMP/
PKA pathway and AROS (active regulator of SIRT1) can
positively regulate SIRT1 (Kim et al. 2007, Chao & Tontonoz
2012). Collectively, our observations suggest that DBC1
levels do not affect the transcriptional activity of STAT5A.
Since there was evidence suggesting that DBC1 may
have a pro-inflammatory role in adipocytes by increasing
the expression of NF-κB-regulated inflammatory cytokines
(Moreno-Navarrete et al. 2015b), we examined the actions
of TNFα on adipocytes with reduced levels of DBC1.
TNFα can induce insulin resistance, in part, through
the transcriptional repression of the Glut4 gene in
adipocytes (Stephens & Pekala 1991, Stephens et al. 1997,
Ruan et al. 2002a) and by activating NF-κB (Ruan et al.
2002b). In addition, TNFα can repress adiponectin gene
expression in mouse and human adipocytes (Fasshauer
et al. 2002, Degawa-Yamauchi et al. 2005). Both increased
GLUT4 protein expression in adipocytes (Carvalho et al.
2005, Atkinson et al. 2013) and increased adiponectin
levels (Fu et al. 2005) are associated with improvements
https://jme.bioscientifica.com
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in insulin sensitivity. Knockdown of DBC1 did not
alter TNFα-mediated induction of pro-inflammatory
MCP-1 or repression of anti-inflammatory adiponectin
(Fig. 5A). However, we consistently observed that a
loss of DBC1 protein resulted in increased Glut4 gene
expression, which suggests a potential role for DBC1 in
glucose regulation. Studies in HepG2 cells have shown a
knockdown of DBC1 results in the upregulation of PEPCK
(phosphoenolpyruvate carboxykinase) and consequently
effects glucose production (Nin et al. 2014). Experiments
performed with inguinal fat tissue from DBC1-null
mice also showed increased PEPCK expression in DBC1deficient tissue (Moreno-Navarrete et al. 2015b). Although
additional experiments will be required to determine if
there are any direct effects of DBC1 on glucose metabolism
or Glut4 gene expression, our results suggest that DBC1
is a likely a negative regulator of GLUT4 in adipocytes
(Fig. 5A).
Although the loss of DBC1 did not profoundly affect
TNFα regulation of several genes in adipocytes (Fig. 5),
we did observe that alteration of DBC1 levels affected
TNFα-induced lipolysis. Our studies revealed a modest
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Figure 6
Knockdown of DBC1 in mature adipocytes modestly suppresses
TNFα-induced lipolysis. Fully differentiated 3T3-L1 adipocytes were
transfected once per day for two days with non-targeting (NT) siRNA or
DBC1 siRNA. After 54 h, media was replaced with incubation media and
cells were treated with 0.75 nM TNFα or equivalent volume of vehicle
(0.1% BSA/PBS) overnight. After 12 h, cells were treated again with
vehicle or TNFα for 2 h. fifty microliters of conditioned medium was used
for free fatty acid assay and glycerol assay. Statistical significance was
determined using a Student’s t-test and assigned as *P < 0.05 and
***P < 0.005. This is a representative figure of an experiment
independently performed two times on different groups of adipocytes.

but significant reduction in glycerol and free fatty acid
release in DBC1-knockdown adipocytes under TNFαstimulated conditions (Fig. 6). This effect could be
considered metabolically favorable, which is also evident
by the increased Glut4 expression we observed with loss
of DBC1. Overall, our observations are consistent with
the phenotype of the DBC1-knockout mice fed a high-fat
diet that are more insulin sensitive and have decreased
circulating FFA (Escande et al. 2015). Our data showing
that loss of DBC1 increases Glut4 expression and reduces
TNFα-induced lipolysis suggests that the loss of DBC1 in
adipocytes may contribute to the metabolically protected
phenotype of the DBC1-null mice. Although additional
experiments in adipocyte-specific DBC1 knockout mice
will be needed, the current data are consistent with a role
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of DBC1 in promoting metabolic dysfunction. Decreased
FFA levels are typically associated with a metabolically
healthy phenotype. Whereas an increase in glycerol
and fatty acids is often harmful and associated with the
clinical manifestations of metabolic syndrome, which also
include obesity and insulin resistance (Boden 1999, Arner
& Rydén 2015). Our results show a decrease in glycerol
and free fatty acid release from TNFα-stimulated DBC1deficient adipocytes that occurs in a cell autonomous
manner and suggest that DBC1 plays a direct or indirect
role in the ability of TNFα to induce lipolysis.
Although these novel observations revealed that DBC1
is present in a protein complex with STAT5A in adipocyte
nuclei (Fig. 1), most of our functional studies reproducibly
generated negative observations. The loss of DBC1 did
not affect STAT5A expression (Fig. 2), STAT5A tyrosine
phosphorylation (Fig. 2) or the expression of STAT5A target
genes (Fig. 4). Although DBC1 is clearly in a complex with
STAT5, and loss of DBC1 did result in expected increase in
SIRT1 activity (Fig. 3), we were unable to perturb STAT5A
expression, activation or activity. We did, however, have
two consistent effects that accompanied loss of DBC1
expression in adipocytes: (1) increased Glut4 expression
and (2) a statistically significant decrease in TNFα-induced
lipolysis. Nevertheless, it is unlikely that these functions
of DBC1 are related to its interaction with STAT5A. Further
studies are needed to identify additional proteins present
in the DBC1/STAT5A complex, to elucidate the function
of the DBC1/STAT5A interaction and to investigate the
mechanism of DBC1’s ability to modulate TNFα-induced
lipolysis.
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